P-263: Effect of inhibition of HMG-co-reductase on carotid intima-media thickness (C-IMT) and sistemic inflammation parameters in type 2 diabetic patients

C-IMT and serum PCR levels are important markers of cardiovascular disease and good predictors of morbidity and mortality in diabetic patients. The purpose of the study was to evaluate the effect of Pravastatin, a potent HMG-Co reductase inhibitor, on C-IMT and sistemic inflammation in patient with type 2 Diabetes Mellitus (DM) and Hypercholesterolemia. 248 patients (146 males; 102 females; age 60.35±7.42) were enrolled and received Pravastatin 40 mg once daily for 24 months. Hypertensive patients with a good farmacological Blood Pressure (BP) control (SBP≤135 mmHg; DBP≤85 mmHg ; all patients were treated with ACE-I, ARB, long acting CCB, Alfa-blockers, Diuretics alone or in combination) after 6 months of treatment continued the study. Exclusion criteria were: 1) Abitual smokers; 2) Artery plaques; 3) Age ≥75; 4) Malignant or grade 3 hypertension (JNC VII); 5) Diabetic Nephropaty; 6) Chronic renal failure (creatinine clearance≤60 ml/min); 7) Congestive heart failure (3⊥- 4⊥ NYHA class ); 8) BMI ≥32; 9) Chronic inflammatory disease or cancer; 10) HbA1c ≥10,5%. C-IMT was measured at baseline (T0) and after 12 months (T1) and 24 months (T2) by high resolution B-mode ultrasonography; BP was monitored at baseline and every 6 months by a Spacelabs 90207 (a non invasive automatic BP measuring device); PCR (as marker of systemic inflammation), LDL-Chol, HDL-Chol, HbA1c serum levels dosed at baseline and every 6 months. 62 patients did not concluded the study; in the remaining patients LDL-Chol (from 154.3±18.4 to 118.4±9.2 mg/dl - p